Enantioselective metabolism of ifosfamide by the kidney

Chirality

Volumn 18, Issue 6, 2006, Pages 398-405

  Aleksa, Katarina ^b   Ito, Shinya ^b   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

CYP2B6; CYP3A; Enantioselective metabolism; Ifosfamide; Kidney; Nephrotoxicity

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A; DRUG METABOLITE; IFOSFAMIDE; N2 DECHLOROETHYLIFOSFAMIDE; N3 DECHLOROETHYLIFOSFAMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANIMAL TISSUE; ARTICLE; CELL CULTURE; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INFANT; KIDNEY METABOLISM; KIDNEY MICROSOME; KIDNEY PROXIMAL TUBULE; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; SWINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IFOSFAMIDE; INFANT; KIDNEY; KIDNEY TUBULES, PROXIMAL; MALE; MICROSOMES; MICROSOMES, LIVER; MIDDLE AGED; MOLECULAR STRUCTURE; STEREOISOMERISM; SUS SCROFA; TIME FACTORS;

EID: 33744961237     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20268     Document Type: Article

References (37)

1. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-5637.
2. Weber GF, Waxman DJ. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 1993;45:1685-1694.
3. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37:301-355.
4. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999; 27:533-541.
5. Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 1999;27:1309-1318.
6. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428-467.
7. Kaijser GP, Korst A, Beijnen JH, Bult A, Underberg WJ. The analysis of ifosfamide and its metabolites (review). Anticancer Res 1993;13: 1311-1324.
8. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994;47:1157-1163.
9. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190.
10. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001;40:41-62.
11. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000;38:291-304.
12. Wainer IW, Ducharme J, Granvil CP. The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 1996;37:332-336.
13. Mulders TM, Keizer, Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin Cancer Res 1995;1:1525-1536.
14. Dubourg L, Taniere P, Cochat P, Baverel G, Michoudet C. Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules. Pediatr Nephrol 2002;17:97-103.
15. Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-79.
16. Goren MP, Wright RK, Pratt CB. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1989;2:1219-1220.
17. Mohrmann M, Kupper N, Schonfield B, Brandis M. Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1). Ren Physiol Biochem 1995;18:118-127.
18. Springate J, Chan K, Lu H, Davies S, Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell Dev Biol Anim 1999;35:314-317.
19. Springate J, Zamlauski-Tucker MJ, Lu H, Chan KK. Renal clearance of ifosfamide. Drug Metab Dispos 1997;25:1081-1082.
20. Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-117.
21. Aleksa K, Ito S, Koren G. Developmental renal tubular toxicity; A hypothetical frame work and experimental approaches. Curr Therap Res Clin Exper 2001;62:930-941.
22. Aleksa K, Halachmi N, Ito S, Koren G. A tubule cell model for ifosfamide nephrotoxicity. Can J Physiol Pharmacol 2005;83:499-508.
23. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr Nephrol 2005;20:872-885.
24. Aleksa K, Ho S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 2004;143:159-162.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
26. Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004;144:285-293.
27. Green CJ. Super order: ungulata; animal anesthesia. London: laboratory Animals Ltd.; 1979. p 163-198.
28. Nielsen TW, Maaske CA, Booth NH. Some Comparative Aspects of Porcine Renal Function; in: Bustad LK, McClellan RO, editors. Swine in biomedical research. Seattle, WA: Pacific Northwest Laboratory, 1966. p 529-536.
29. Koren G, Barker C, Bohn D, Kent G, Biggar WD. Influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. Crit Care Med 1985;13:844-847.
30. Masurel D, Houghton PJ, Young CL, Wainer IW. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. Cancer Res 1990;50:252-255.
31. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 87:485-505.
32. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 2001;29: 967-975.
33. Kerbusch T, de Kraker J, Mathjt RA, Beijne JH. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinet 2001;40:615-625.
34. Wagner T. Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994;26:439-456.
35. Boddy AV, Cole M, Pearson AD, Idle JR. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995;36:53-60.
36. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993;33:36-42.
37. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990;30:725-732.